VivoSeq
Other

PAH

1

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

PAH is an early-stage landscape with 1 program across 6 companies. The most active players are Novartis, United Therapeutics, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

70/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1United Therapeutics logo

United Therapeutics

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalP

PhaseBio Pharmaceuticals Inc.

0 programs

PreclinicalL

Lung Biotechnology PBC

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

XBD173

Novartis

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Completed7 · 54%
Terminated2 · 15%
Unknown status1 · 8%
Withdrawn1 · 8%
Enrolling by invitation1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Not yet recruiting·UUniversity Hospital, Strasbourg, France·Preclinical·NCT07697235·22 enrolled
Investigating the Relationship Between Endothelial Cell Activation and Total Pulmonary Resistance in Pulmonary Artery Hypertension (PAH)
Enrolling by invitation·IImperial College London·Phase 1·NCT07697183·6 enrolled
Ultralow Dose PAH Binary Mixture Study
Completed·OOregon State University·Phase 1·NCT03631667·8 enrolled
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Completed·United Therapeutics logoUnited Therapeutics·N/A·NCT01266265·1,333 enrolled
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
Completed·United Therapeutics logoUnited Therapeutics·Phase 4·NCT02847260·39 enrolled
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
Completed·United Therapeutics logoUnited Therapeutics·Phase 1·NCT03950739·51 enrolled
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Completed·LLung Biotechnology PBC·Phase 2·NCT00781885·19 enrolled
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02112487·88 enrolled
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
Completed·Bayer logoBayer·Phase 1/2·NCT02032836·27 enrolled
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
Terminated·PPhaseBio Pharmaceuticals Inc.·Phase 2·NCT03795428·25 enrolled
Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01847014·4 enrolled
Inhaled Treprostinil for PAH: Open-label Extension
Withdrawn·United Therapeutics logoUnited Therapeutics·Phase 3·NCT01557660
Beta-blockers in i-PAH
Unknown status·AAmsterdam UMC, location VUmc·Phase 1/2·NCT01246037·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)